New nasal spray vaccine aims to stop COVID at the nose
NCT ID NCT06026514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new COVID-19 vaccine given as a nasal spray. It involved 27 healthy adults aged 18 to 50. The vaccine uses a weakened virus to teach the body to fight SARS-CoV-2. The main goal was to check safety and see if the vaccine triggers an immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 20215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a digital swab test tell COVID and flu apart at home?
- Sniffing your way back: does scent therapy rebuild COVID-Shattered smell?
- Long-Term heart risks after rare COVID complication in kids under scrutiny
- Which COVID-19 shot causes fewer side effects? new study compares novavax and pfizer
- New study tracks immune clues in seniors with flu, RSV, and COVID-19
- MRI study seeks clues to COVID brain fog